2 No-Brainer Stocks to Buy in Biotech
For investors who want to add companies that enjoy stability and reliable growth to their portfolios, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) are easy quick picks. Both are consistently profitable, cash-rich, and have a history of delivering for shareholders in the form of dividends or stock buybacks. As importantly, each boasts a diverse drug development pipeline that's chock-full of late-stage programs approaching potential regulatory approvals and market entry over the next few years.
Amgen and Biogen are set to report their third quarter earnings as well as updates from several key clinical trials next month. As early as 2021, expected approvals of new drugs may also lift the year-over-year quarterly sales revenues of both companies from their single-digit percentage points, driving growth in the process. Let's investigate in more detail what they biotech stocks have been up to and why they deserve a spot in your portfolio sooner rather than later.
Image source: Getty Images.
Source Fool.com
